Infosys a Top 100 Global Brand for 2025. Achieves 34% Brand Value Surge, Ranks among the Top 5% of Most Trusted Brands in the U.S.
"Our efforts are relentlessly focused on building Infosys into one of the most respected IT services brands in the world, differentiated by our expertise and innovation in helping our clients navigate an AI-first world. Even as we evolve to remain relevant to the changing needs of our stakeholders, our brand remains unchanging in its commitment to live our purpose - amplifying human potential and creating the next opportunity for all," said Sumit Virmani, Global Chief Marketing Officer, Infosys. "We are pleased to see our brand value continue to grow, and Infosys be trusted and counted among the most valuable global brands," he added.
The Kantar BrandZ recognition underscores our ability to strategically balance the timelessness of our brand with the timeliness of the reinventions we are making to be able to help our clients transform themselves to succeed in these times of uncertainty, ceaseless disruption, and pervasive AI. Our leadership in enterprise AI is backed by our now market dominating sub brands Infosys Topaz for AI-powered solutions and Infosys Cobalt for enterprise cloud. We continue growing mindshare for Infosys in the AI for enterprises space and have most recently added another sub brand Infosys Aster bringing our AI-amplified marketing suite for enterprises. Brand Finance, the world's leading brand valuation firm, recognized us, earlier this year, as the Top 3 IT services brand, and the fastest growing brand in the industry, over a 5-year period.
"By drawing on the depth of BrandZ's database over the last quarter of a century, our insights show that with the right level of investment and strategic focus, brands have huge potential to drive growth for their owners," said Martin Guerrieria, Head of Kantar BrandZ. "The growing demand for AI technologies puts Infosys in a prime position to capitalise on its brand value and the trust it has earned with its growing customer base."
Beyond business, the brand continues to be trusted as a responsible corporate citizen steering positive change in the communities we work and live in. Through the giving back programs driven by Infosys Foundation we are actively working in the areas of healthcare, education, sustainability, and women empowerment. The Infosys Springboard initiative has already helped build digital skills by providing free learning programs to 12 million people around the world. Infosys continues to be carbon neutral with aspirations to remain at the forefront of sustainability. Infosys was also recognized by Ethisphere, once again, in 2025, among the world's most ethical companies.
About Kantar BrandZ Most Valuable Global Brands
The global ranking, which marks its 20th anniversary in 2025, has become an authoritative source for understanding the value and impact of brands in a dynamic market landscape and highlights the ongoing challenges that marketers face in an era of volatility, uncertainty, complexity and ambiguity. Published annually, the Kantar BrandZ Most Valuable Global Brands report ranks the world's top brands across categories, providing valuable insights into shifting consumer preferences, brand performance, and industry trends. The foundation of Kantar BrandZ lies in its robust methodology, which combines consumer perceptions with financial data to present a holistic view of a brand's value as a corporate asset.
About Infosys
Infosys is a global leader in next-generation digital services and consulting. Over 300,000 of our people work to amplify human potential and create the next opportunity for people, businesses and communities. We enable clients in more than 56 countries to navigate their digital transformation. With over four decades of experience in managing the systems and workings of global enterprises, we expertly steer clients, as they navigate their digital transformation powered by cloud and AI. We enable them with an AI-first core, empower the business with agile digital at scale and drive continuous improvement with always-on learning through the transfer of digital skills, expertise, and ideas from our innovation ecosystem. We are deeply committed to being a well-governed, environmentally sustainable organization where diverse talent thrives in an inclusive workplace.
Visit www.infosys.com to see how Infosys (NSE, BSE, NYSE: INFY) can help your enterprise navigate your next.
Safe Harbor
Certain statements in this release concerning our future growth prospects, or our future financial or operating performance, are forward-looking statements intended to qualify for the 'safe harbor' under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results or outcomes to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the execution of our business strategy, increased competition for talent, our ability to attract and retain personnel, increase in wages, investments to reskill our employees, our ability to effectively implement a hybrid work model, economic uncertainties and geo-political situations, technological disruptions and innovations such as Generative AI, the complex and evolving regulatory landscape including immigration regulation changes, our ESG vision, our capital allocation policy and expectations concerning our market position, future operations, margins, profitability, liquidity, capital resources, our corporate actions including acquisitions, and cybersecurity matters. Important factors that may cause actual results or outcomes to differ from those implied by the forward-looking statements are discussed in more detail in our US Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2024. These filings are available at www.sec.gov. Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company's filings with the Securities and Exchange Commission and our reports to shareholders. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
9 hours ago
- Korea Herald
Seegene Unveils CURECA™ and STAgora™ at ADLM 2025, Advancing the Next Stage of Diagnostics
SEOUL, South Korea, Aug. 5, 2025 /PRNewswire/ -- Seegene Inc., a global leader in molecular diagnostics, unveiled two new technologies at ADLM 2025 in Chicago (July 29–31) designed to advance laboratory automation and data-driven infectious disease monitoring. The company introduced CURECA™, world's first fully unattended PCR automation system, and STAgora™, a real-time data analytics platform intended to support earlier detection and precision care. Chairman Highlights Next Step in Molecular Diagnostics "With CURECA™ and STAgora™, we are taking an important step toward the future of diagnostics," said Dr. Jong-Yoon Chun, Chairman and CEO of Seegene, during a press conference with U.S. and global media on July 30. "Our goal is to enable laboratories worldwide to automate complex testing workflows and use diagnostic data more effectively, ultimately helping advance global efforts toward a world free from diseases." Today, most molecular testing systems remain only partially automated, dependent on skilled personnel for repetitive manual steps and fixed workflows that limit efficiency and scalability. CURECA™ Breaks the Limits of Automation to Reshape Global Diagnostics CURECA™ is the first system in the diagnostics industry designed to fully automate every step of PCR testing, including the traditionally manual pre-treatment stage. Seegene notes that achieving true full automation in diagnostics requires three key conditions: operation without highly trained professionals, continuous 24-hour processing, and uninterrupted specimen input. CURECA™ is designed to meet all three. Its dedicated module, CURECA™ Prep, processes a wide range of specimen types such as urine, blood, sputum, and stool, addressing one of the most persistent barriers to automation. With the module handling diverse specimen pre-treatment, the full CURECA™ system completes the entire PCR workflow from sample loading through nucleic acid extraction, amplification, and result analysis without manual intervention. The system is engineered for continuous 24-hour operation, aiming to minimize human error, improve workflow efficiency, and allow laboratories to allocate skilled staff to higher-value activities. Full automation has long been a challenge in diagnostics due to specimen variability and the reliance on trained personnel for repetitive pre-processing tasks. CURECA™ is intended to help laboratories overcome these constraints by providing a scalable and adaptable system that can be configured to fit different lab sizes and workflows. CURECA™ Prep could also potentially extend to other testing fields, such as clinical chemistry and immunodiagnostics, as Seegene continues to explore broader automation solutions. STAgora™ Transforms Diagnostic Data into Real-Time Clinical Intelligence STAgora™ is Seegene's latest platform, designed to collect and analyze PCR testing data in real time, providing laboratories with broader context to inform diagnostic workflows. The platform includes more than 40 analytical tools, offering functions such as infection trend tracking, hospital-level positivity monitoring, and multi-pathogen co-infection pattern analysis. Rather than serving as a simple data repository, STAgora™ is built as an integrated platform intended to help laboratories derive meaningful, aggregated insights from testing data. Today, individual test results often provide limited information without broader reference points. STAgora™ is designed to address this by enabling hospitals to build their own statistical datasets and compare aggregated data across institutions, helping them detect infection patterns faster and support more informed decision-making. The data shared through the platform is de-identified and formatted according to each institution's requirements, supporting secure, real-time exchange at local, national, or global levels. Advancing Toward a World Free from All Diseases Dr. Chun reiterated Seegene's long-term vision of building "a world free from diseases" noting that the introduction of CURECA™ and STAgora™ completes the company's five core technology pillars. These include Seegene's proprietary PCR technology, the SGDDS (Seegene Digitalized Development System) for automated assay development, its global Technology-Sharing Initiative, and now the addition of fully automated PCR testing and real-time data analytics capabilities. Industry experts at ADLM 2025 expressed strong interest in Seegene's new technologies. Jamel Giuma, President and CEO of Miami based laboratory IT consulting firm JTG Consulting Group, said, "I've attended many ADLM conferences over the years, and CURECA™ is one of the most innovative solutions I have seen so far. I believe it has the potential to simplify laboratory workflows, reduce the burden on lab personnel, and greatly enhance overall operational efficiency." "With CURECA™ and STAgora™, we're addressing long-standing barriers in molecular diagnostics," Dr. Chun added. "Just as smartphones and electric vehicles transformed their industries, we believe these technologies will redefine what is possible in diagnostic testing, helping laboratories worldwide achieve true automation, unlock the value of diagnostic data, and ultimately contribute to building a world free from diseases." Disclaimer CURECA™ and STAgora™ demonstrated at ADLM 2025 are pre-commercial technologies under development, not commercially available, and are not currently cleared for clinical diagnostic use in any jurisdiction.
Korea Herald
12 hours ago
- Korea Herald
iNtRON Bio, Demonstrated Toxin-Neutralizing Effect of IMPA™ Phage Engineering Technology in Colorectal Cancer Model and Completed the US Patent Application
• Successful validation of payloaded anti-colibactin toxin phage using IMPA ™ technology • Demonstrated ' Dual-target Therapeutic Strategy ' by bacterial eradication and toxin neutralization • Filed the US patent application for the candidate substance and preclinical studies including PoC underway BOSTON and SEOUL, South Korea, Aug. 5, 2025 /PRNewswire/ -- Recently, a specific genotype of E. coli that may cause colorectal cancer has been detected in commonly eaten leafy vegetables such as lettuce, raising consumer concerns. Among these strains, pks+ E. coli is of particular concern. This bacterium produces a toxic substance in the intestine that causes DNA damage (ICLs, Interstrand Cross-Links), which leads to DSBs (Double Strand Breaks), and has been shown in numerous studies, including Nature (2023), to increase the risk of colorectal cancer over time. Amid this situation, as an innovative bacteriophage technology development company, iNtRON Bio proposes a new possibility for microbiome-based anticancer drugs in treating colorectal cancer—considered a hard-to-treat disease—by applying our phage engineering technology called IMPA™. iNtRON Bio has been developing PHAGERIA Ⓡ, an immunotherapeutic targeting gut bacteria, and through the IMPA™ phage engineering technology developed in-house, iNtRON Bio has secured a new drug candidate payloaded with a substance that effectively eliminates colibactin ,a major causative agent of colorectal cancer and have filed a related US patent application. The phage engineering technology IMPA™ (Intelligent Modular Phage Assembly) was formerly known as the "robot bacteriophage." With the recent US patent application, it was named to clearly reflect the function as a technology for engineering modular phages (mock-up phages) that can carry therapeutic payloads. This achievement is the result of combining transposon mutagenesis, CRISPR/Cas-based forward/reverse genetics, and AI-driven analysis capabilities to explore the possibility of delivering various functional payloads. In particular, it is highly significant that iNtRON Bio successfully loaded a payload targeting colibactin ,deeply involved in colorectal cancer, onto the surface of the phage and, for the first time globally, confirmed its effectiveness. In other words, iNtRON Bio has demonstrated a dual-targeting therapeutic approach that not only eliminates pks+ E. coli, which is a main cause of colorectal cancer, but also neutralizes the toxin secreted by this bacterium. This includes verifying colibactin's role in cancer development, confirming the suppressive effect of modular phage on colorectal cancer, and proving the phage's colibactin-degrading ability—resulting in successful proof-of-concept studies and related patent acquisition. Simply put, the core of this development is that a colibactin-degrading protein was applied as a payload on the phage's protein shell, known as the capsid. Like a precision-guided missile with a warhead, the engineered phage specifically infects pks+ E. coli, kills the bacteria, and at the same time removes the colibactin toxin already secreted by the bacterium using the enzyme carried in the capsid—offering a dual therapeutic effect. Recently, the field of bacteriophage engineering is gaining attention globally. IMPA™ technology is not only a unique platform technology differentiated from other companies, but also serves as strong evidence that it can function as an actual drug delivery platform beyond simple research use. It is encouraging that iNtRON Bio's research has overcome key limitations of conventional phage-based technologies, such as decreased payload activity and phage structural instability when therapeutic substances are loaded. By confirming that the payload retains its original function, iNtRON Bio has demonstrated that it has successfully overcome high technical hurdles. The engineered phages are not merely for research purposes but were selected and validated through multiple tests with real-world and human applications in mind. iNtRON Bio has applied an advanced AI-driven optimization platform technology, refined it with great care, and plan to extend its application to other development fields for ongoing innovation. This achievement is not only a remarkable advancement in phage engineering technology but will also become a driving force for discovering innovative microbiome drug candidates through integration with other phage-based platform technologies of iNtRON Bio. It will proceed smoothly with preclinical studies including proof-of-concept (PoC) testing for combination effects with existing colorectal cancer therapies. In addition, IMPA™ phage engineering technology will be applied more broadly to ADC drug development, anti-cancer agent, and vaccines, as iNtRON Bio continues to strengthen our global technological competitiveness in these fields.
Korea Herald
12 hours ago
- Korea Herald
Precision-Matched Meat Sourcing: The Global Advantage at FHC2025
SHANGHAI, Aug. 5, 2025 /PRNewswire/ -- FHC Shanghai Global Food Trade Show, Asia's flagship international food trade fair, returns to the Shanghai New International Expo Centre (SNIEC) from November 12-14, 2025. China's Visa Policy Opens Doors for Global Meat Commerce Leveraging China's expansive visa-free access for 54 nations, FHC2025 presents an unrivaled opportunity for the international meat industry. Suppliers and buyers gain frictionless entry for pivotal 15-day business engagements. Exhibitors enjoy expedited entry with invitations and 24-hour visa-on-arrival at key ports like Shanghai. Discover the Future of Meat at Asia's Premier Food Epicenter Occupying 200,000 sqm, FHC2025 spotlights the meat sector, building on 2024's resounding success (171,828 trade visitors, 3,000+ global exhibitors). Dedicated showcases from leading meat nations will be unveiled. Expect robust participation from international pavilions representing key players like Brazil, the USA, the EU, and Australia. Witness the convergence of global trends: premium and specialty cuts, sustainable sourcing and traceability solutions, advanced processing technologies, and the booming ready-to-eat/cook segments, all within Shanghai. Precision-Matched Connections with High-Value Meat Buyers The globally acclaimed FHC Hosted Buyer Program offers meat suppliers priority access to high-value procurement channels. Participants gain: Guaranteed High-Impact Meetings: Secure 50+ pre-vetted appointments with premium hotel procurement directors, chain restaurant central kitchen heads, and specialized meat importers. Direct Access to Decision Makers: Engage F&B association leaders and hospitality group executives face-to-face, slashing negotiation cycles by 60%. Actionable Market Intelligence: Gain critical insights into China's $150 billion meat market dynamics and evolving import regulations. VIP Advantage: Enjoy all VIP benefits including access to the VIP Lounge, welcome package and accommodation during the exhibition period (Only for VIP delegations).
